MedPath

Torsemide

These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS TORSEMIDE tablets, for oral use Initial U.S. Approval: 1993

Approved
Approval ID

03fbbb85-4e0f-4f3b-b4b0-87f84cb33d47

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 30, 2023

Manufacturers
FDA

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

DUNS: 780779901

Products 4

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Torsemide

PRODUCT DETAILS

NDC Product Code23155-873
Application NumberANDA076894
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJuly 17, 2023
Generic NameTorsemide

INGREDIENTS (6)

TORSEMIDEActive
Quantity: 20 mg in 1 1
Code: W31X2H97FB
Classification: ACTIB
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
CROSPOVIDONE, UNSPECIFIEDInactive
Code: 2S7830E561
Classification: IACT

Torsemide

PRODUCT DETAILS

NDC Product Code23155-872
Application NumberANDA076894
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJuly 17, 2023
Generic NameTorsemide

INGREDIENTS (6)

TORSEMIDEActive
Quantity: 10 mg in 1 1
Code: W31X2H97FB
Classification: ACTIB
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
CROSPOVIDONE, UNSPECIFIEDInactive
Code: 2S7830E561
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

Torsemide

PRODUCT DETAILS

NDC Product Code23155-871
Application NumberANDA076894
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJuly 17, 2023
Generic NameTorsemide

INGREDIENTS (6)

TORSEMIDEActive
Quantity: 5 mg in 1 1
Code: W31X2H97FB
Classification: ACTIB
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
CROSPOVIDONE, UNSPECIFIEDInactive
Code: 2S7830E561
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

Torsemide

PRODUCT DETAILS

NDC Product Code23155-874
Application NumberANDA076894
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJuly 17, 2023
Generic NameTorsemide

INGREDIENTS (6)

MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
TORSEMIDEActive
Quantity: 100 mg in 1 1
Code: W31X2H97FB
Classification: ACTIB
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
CROSPOVIDONE, UNSPECIFIEDInactive
Code: 2S7830E561
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT

Drug Labeling Information

WARNINGS AND PRECAUTIONS SECTION

LOINC: 43685-7Updated: 2/24/2022

5 WARNINGS AND PRECAUTIONS

5.1 Hypotension and Worsening Renal Function

Excessive diuresis may cause potentially symptomatic dehydration, blood volume reduction and hypotension and worsening renal function, including acute renal failure particularly in salt-depleted patients or those taking renin- angiotensin aldosterone inhibitors. Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). Monitor volume status and renal function periodically.

5.2 Electrolyte and Metabolic Abnormalities

Torsemide can cause potentially symptomatic hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia, and hypochloremic alkalosis. Treatment with torsemide can cause an increase in blood glucose levels and hyperglycemia. Asymptomatic hyperuricemia can occur and gout may rarely be precipitated. Monitor serum electrolytes and blood glucose periodically.

5.3 Ototoxicity

Tinnitus and hearing loss (usually reversible) have been observed with loop diuretics, including torsemide. Higher than recommended doses, severe renal impairment, and hypoproteinemia, appear to increase the risk of ototoxicity.

Key Highlight
  • Hypotension and worsening renal function: monitor volume status and renal function periodically (5.1)
  • Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. (5.2)
  • Ototoxicity (5.3, 7.6)

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 7/3/2023

2 DOSAGE AND ADMINISTRATION

2.1 Treatment of Edema

Edema associated with heart failure

The recommended initial dose is 10 mg or 20 mg oral torsemide once daily. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 200 mg have not been adequately studied.

Edema associated with chronic renal failure

The recommended initial dose is 20 mg oral torsemide once daily. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 200 mg have not been adequately studied.

Edema associated with hepatic cirrhosis

The recommended initial dose is 5 mg or 10 mg oral torsemide once daily, administered together with an aldosterone antagonist or a potassium-sparing diuretic. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 40 mg have not been adequately studied in this population.

2.2 Treatment of Hypertension

The recommended initial dose is 5 mg once daily. If the 5 mg dose does not provide adequate reduction in blood pressure within 4 to 6 weeks, increase to 10 mg once daily. If the response to 10 mg is insufficient, add another antihypertensive agent to the treatment regimen.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Torsemide - FDA Drug Approval Details